Alnylam Competitors and Similar CompaniesClear all
Alnylam's competitors and similar companies include Celyad, Sorrento Therapeutics, CureVac and Regulus Therapeutics.
 Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Sorrento Therapeutics Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
|  Regulus Therapeutics Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs. | ||
Founding Date | Founding Date 2002 | Founding Date 2007 | Founding Date 2006 | Founding Date 2000 | Founding Date 2007 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Mont-Saint-Guibert, BE HQ New York, US | Locations San Diego, US HQ San Diego, US | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations San Diego, US HQ | |
Employees | Employees 1,32324% increase | Employees 17 | Employees 31019% decrease | Employees 999 | Employees 2462% decrease |
Valuation ($) | Valuation ($) 36.5 b | Valuation ($) 11.8 m | Valuation ($) 1.5 m | Valuation ($) 648.3 m | Valuation ($) 105.4 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $1.8b (FY, 2023) | Revenue (est.) €102k (FY, 2023) | Revenue (est.) $62.8m (FY, 2022) | Revenue (est.) €53.8m (FY, 2023) | Revenue (est.) N/A |
Cost of goods | Cost of goods $268.2m (FY, 2023) | Cost of goods €69k (FY, 2023) | Cost of goods N/A | Cost of goods €64.3m (FY, 2023) | Cost of goods N/A |
Gross profit | Gross profit $1.6b (FY, 2023) | Gross profit €1.4m (FY, 2023) | Gross profit N/A | Gross profit (€2.6m) (FY, 2023) | Gross profit N/A |
Net income | Net income ($440.2m) (FY, 2023) | Net income (€8.4m) (FY, 2023) | Net income ($577.8m) (FY, 2022) | Net income (€260.2m) (FY, 2023) | Net income ($30m) (FY, 2023) |
Operating ⚠ | |||||
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued 233 (May, 2020) | Patents Issued 300 (FY, 2016) |
Funding | |||||
Total funding raised | Total funding raised $ 1.5b | Total funding raised N/A | Total funding raised $ 42.6m | Total funding raised $ 1.1b | Total funding raised $ 10m |
For sources of this data, please see the company profile
View Company Profiles
Celyad
HQ
Mont-Saint-Guibert, BE
Employees
17
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companySorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
View company
CureVac
HQ
Tübingen, DE
Employees
999
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View companyRegulus Therapeutics
HQ
San Diego, US
Employees
24
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
View company